Raymond James Financial Services Advisors, Inc. Adma Biologics, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 551,887 shares of ADMA stock, worth $11 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

551,887

Previous 583,357 5.39%

Holding current value

$11 Million

Previous $6.52 Million 69.18%

% of portfolio

0.02%

Previous 0.01%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$11.21 - $20.03 $352,778 - $630,344	-31,470 Reduced 5.39%	551,887 $11 Million
Q2 2024 Jul 19, 2024	BUY	$5.98 - $11.18 $1.93 Million - $3.61 Million	322,911 Added 123.98%	583,357 $6.52 Million
Q1 2024 Apr 22, 2024	BUY	$4.4 - $6.74 $124,062 - $190,041	28,196 Added 12.14%	260,446 $1.72 Million
Q4 2023 Jan 16, 2024	SELL	$3.08 - $4.52 $49,979 - $73,346	-16,227 Reduced 6.53%	232,250 $1.05 Million
Q3 2023 Oct 24, 2023	BUY	$3.47 - $4.61 $359,020 - $476,969	103,464 Added 71.35%	248,477 $889,000
Q2 2023 Jul 25, 2023	SELL	$3.12 - $4.22 $39,202 - $53,024	-12,565 Reduced 7.97%	145,013 $535,000
Q1 2023 Apr 14, 2023	SELL	$3.01 - $3.87 $15,408 - $19,810	-5,119 Reduced 3.15%	157,578 $521,000
Q4 2022 Feb 08, 2023	BUY	$2.47 - $3.88 $38,687 - $60,772	15,663 Added 10.65%	162,697 $631,000
Q3 2022 Oct 25, 2022	SELL	$2.03 - $2.86 $189,961 - $267,630	-93,577 Reduced 38.89%	147,034 $357,000
Q2 2022 Aug 12, 2022	BUY	$1.43 - $2.2 $151,845 - $233,609	106,186 Added 78.99%	240,611 $476,000
Q1 2022 May 11, 2022	SELL	$1.28 - $1.83 $670 - $958	-524 Reduced 0.39%	134,425 $246,000
Q4 2021 Feb 08, 2022	BUY	$1.09 - $1.66 $28,244 - $43,013	25,912 Added 23.76%	134,949 $190,000
Q3 2021 Nov 02, 2021	BUY	$1.13 - $1.65 $38,510 - $56,232	34,080 Added 45.47%	109,037 $123,000
Q2 2021 Aug 11, 2021	SELL	$1.51 - $2.07 $684 - $937	-453 Reduced 0.6%	74,957 $120,000
Q1 2021 May 14, 2021	BUY	$1.67 - $2.95 $57,461 - $101,503	34,408 Added 83.92%	75,410 $133,000
Q4 2020 Feb 12, 2021	BUY	$1.8 - $2.56 $2,163 - $3,077	1,202 Added 3.02%	41,002 $80,000
Q3 2020 Nov 04, 2020	SELL	$2.04 - $3.74 $3,927 - $7,199	-1,925 Reduced 4.61%	39,800 $95,000
Q2 2020 Jul 17, 2020	BUY	$2.42 - $3.29 $100,974 - $137,275	41,725 New	41,725 $122,000
Q4 2018 Feb 11, 2019	SELL	$2.17 - $6.12 $51,429 - $145,044	-23,700 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$4.39 - $6.85 $38,632 - $60,280	8,800 Added 59.06%	23,700 $147,000
Q2 2018 Jul 30, 2018	BUY	$4.39 - $5.44 $65,410 - $81,056	14,900 New	14,900 $67,000

Others Institutions Holding ADMA

# of Institutions

378

Shares Held

188M

Call Options Held

2.53M

Put Options Held

696K

View Full List

About ADMA BIOLOGICS, INC.

Ticker ADMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 196,356,992
Market Cap $3.92B
Description
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...

More about ADMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account

Raymond James Financial Services Advisors, Inc. Adma Biologics, Inc. Transaction History